Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small... von Goldman, Jonathan W., Cummings, Amy Lauren, Mendenhall, Melody A., Velez, Maria A, Babu, Sunil, Johnson, Tirrell T., Alcantar, Juan M., Dakhil, Shaker R., Kanamori, David E., Lawler, William E., Anand, Sidharth, Chauv, James, Garon, Edward B., Slamon, Dennis J.

Volltext

UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer von Goldman, Jonathan W., Cummings, Amy Lauren, Arzoo, Karo K., Hu, Eddie Hong-Lung, Garon, Edward B., Kirimis, Evangelia K., Olevsky, Olga, DiCarlo, Brian Anthony, Davidson, Sheldon J., Kaul, Anita, Noor, Zorawar Singh, Mendenhall, Melody A., Wong, Deborah J.L., Huang, Holly K.T., Velez, Maria A, Chauv, James, Yarden, Yosef, Slamon, Dennis J.

Volltext

TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer von Hurvitz, Sara A., Peddi, Parvin F., Tetef, Merry L., McAndrew, Nicholas Patrick, Master, Aashini K., DiNome, Maggie L., Lee, Minna K, Wang, Lisa S., Spring, Laura, Kivork, Christine, Chauv, James, Bardia, Aditya

Volltext

TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer von Hurvitz, Sara A., Wang, Lisa S., Chan, David, Phan, Vu, Lomis, Thomas, McAndrew, Nicholas Patrick, Spring, Laura, Tetef, Merry L., Villa, Deborah, Applebaum, Steven, Chamberlain, Erin, Dakhil, Shaker R., DiCarlo, Brian Anthony, Kim, David D., Kirimis, Evangelia K., Lawler, William E., Master, Aashini K., Kivork, Christine, Chauv, James, Bardia, Aditya

Volltext

Abstract OT1-12-05: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer von Hurvitz, Sara, Bardia, Aditya, Tetef, Merry L., McAndrew, Nicholas P., Applebaum, Steven, Master, Aashini K., DiNome, Maggie L., Lee, Minna K., Kirimis, Evangelia, Kim, David D., Wang, Lisa S., Greene, Kyle, Phan, Vu, Abdulla, Nihal, Chan, David, Spring, Laura M., Kivork, Christine, Chauv, James

Volltext

Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer von Bardia, Aditya, Hurvitz, Sara, Press, Michael F., Wang, Lisa S., McAndrew, Nicholas P., Chan, David, Phan, Vu, Villa, Deborah, Tetef, Merry L., Chamberlain, Erin, Abdulla, Nihal, Lomis, Thomas, Spring, Laura M., Applebaum, Steven, Dakhil, Shaker, DiCarlo, Brian, Kim, David D., Kirimis, Evangelia, Lawler, William E., Master, Aashini K., McCann, Kelly, Hayashi, Edwin, Kivork, Christine, Chauv, James

Volltext